Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

SER-AP-ES

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

Standard Dose
25MG;15MG;0.1MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview SER-AP-ES is listed in Drugs@FDA under application 012193 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE Form and strength TABLET;ORAL - 25MG;15MG;0.1MG Sponsor NOVARTIS Submission history Latest submission status date: 1992-02-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview SER-AP-ES is listed in Drugs@FDA under application 012193 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE Form and strength TABLET;ORAL - 25MG;15MG;0.1MG Sponsor NOVARTIS Submission history Latest submission status date: 1992-02-28 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
SER-AP-ES (HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE) | Drug Monograph | MedicHelpline